GI pharmaceutical company closes $60M fundraising round — 3 insights

Gastroenterology-focused pharmaceutical company Landos Biopharma closed a $60 million series B financing round.

What you should know:

1. RTW Investments and Perceptive Advisors co-led the fund, with Osage University Partners and entities affiliated with Paul Manning contributing.

2. The company will use the funds to support the development of its ulcerative colitis and Crohn's disease drug candidate, as well as additional pipeline candidates.

3. RTW Investments and Perceptive Advisors each appointed a person to Landos' board as a result of the investment.

More articles on surgery centers:
10 ASC industry key notes
Pennsylvania ASC plans to take Horizon insurance
7 ASCs, surgeons introducing robotics in 2019

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months